Company intelligence / Profile preview

BeBetter Pharma

Yantai, Shandong, Chinabebettermed.com ↗

Ownership: Private
Employees: ~150
Development stage: Other

Overview

BeBetter Pharma is currently advancing its lead candidate, BBI-801, through Phase 2 clinical trials for the treatment of gout and hyperuricemia. The company is also actively conducting Phase 1/2 trials for its epigenetic oncology assets, including BET and EZH2 inhibitors, demonstrating safety and preliminary efficacy in solid tumors and lymphomas.

Therapeutic areas: OncologyRheumatologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Partnerships

CSPC Pharmaceutical Group

Beyond the preview

Go deeper on BeBetter Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BeBetter Pharma.